Aarti Drugs Statistics

Total Valuation

Aarti Drugs has a market cap or net worth of INR 43.68 billion. The enterprise value is 49.61 billion.

Market Cap	43.68B
Enterprise Value	49.61B

Important Dates

The next estimated earnings date is Thursday, July 24, 2025.

Earnings Date	Jul 24, 2025
Ex-Dividend Date	Feb 4, 2025

Share Statistics

Current Share Class	91.94M
Shares Outstanding	n/a
Shares Change (YoY)	-0.32%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	35.72M

Valuation Ratios

The trailing PE ratio is 25.97 and the forward PE ratio is 20.59.

PE Ratio	25.97
Forward PE	20.59
PS Ratio	1.83
PB Ratio	3.19
P/TBV Ratio	3.21
P/FCF Ratio	64.79
P/OCF Ratio	17.86
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.28, with an EV/FCF ratio of 73.58.

EV / Earnings	29.50
EV / Sales	2.08
EV / EBITDA	17.28
EV / EBIT	21.45
EV / FCF	73.58

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.45.

Current Ratio	1.60
Quick Ratio	0.94
Debt / Equity	0.45
Debt / EBITDA	2.14
Debt / FCF	9.12
Interest Coverage	6.45

Financial Efficiency

Return on equity (ROE) is 12.68% and return on invested capital (ROIC) is 7.55%.

Return on Equity (ROE)	12.68%
Return on Assets (ROA)	5.77%
Return on Invested Capital (ROIC)	7.55%
Return on Capital Employed (ROCE)	13.31%
Revenue Per Employee	22.43M
Profits Per Employee	1.58M
Employee Count	1,064
Asset Turnover	0.95
Inventory Turnover	3.22

Taxes

In the past 12 months, Aarti Drugs has paid 436.80 million in taxes.

Income Tax	436.80M
Effective Tax Rate	20.63%

Stock Price Statistics

The stock price has decreased by -13.45% in the last 52 weeks. The beta is 0.41, so Aarti Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	-13.45%
50-Day Moving Average	451.68
200-Day Moving Average	433.63
Relative Strength Index (RSI)	58.43
Average Volume (20 Days)	340,378

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aarti Drugs had revenue of INR 23.87 billion and earned 1.68 billion in profits. Earnings per share was 18.35.

Revenue	23.87B
Gross Profit	8.45B
Operating Income	2.31B
Pretax Income	2.12B
Net Income	1.68B
EBITDA	2.87B
EBIT	2.31B
Earnings Per Share (EPS)	18.35

Full Income Statement

Balance Sheet

The company has 226.10 million in cash and 6.15 billion in debt, giving a net cash position of -5.92 billion.

Cash & Cash Equivalents	226.10M
Total Debt	6.15B
Net Cash	-5.92B
Net Cash Per Share	n/a
Equity (Book Value)	13.69B
Book Value Per Share	149.84
Working Capital	5.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.45 billion and capital expenditures -1.77 billion, giving a free cash flow of 674.20 million.

Operating Cash Flow	2.45B
Capital Expenditures	-1.77B
Free Cash Flow	674.20M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 35.40%, with operating and profit margins of 9.69% and 7.04%.

Gross Margin	35.40%
Operating Margin	9.69%
Pretax Margin	8.87%
Profit Margin	7.04%
EBITDA Margin	12.03%
EBIT Margin	9.69%
FCF Margin	2.82%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.21%.

Dividend Per Share	1.00
Dividend Yield	0.21%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	5.39%
Buyback Yield	0.32%
Shareholder Yield	0.53%
Earnings Yield	3.85%
FCF Yield	1.54%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 30, 2020. It was a forward split with a ratio of 4.

Last Split Date	Sep 30, 2020
Split Type	Forward
Split Ratio	4

Scores

Altman Z-Score	n/a
Piotroski F-Score	5